Longeveron LLC (LGVN)

Currency in USD
0.513
+0.002(+0.39%)
Closed·
0.511-0.002(-0.43%)
·
LGVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.5100.531
52 wk Range
0.4921.920
Key Statistics
Prev. Close
0.511
Open
0.52
Day's Range
0.51-0.531
52 wk Range
0.492-1.92
Volume
81.21K
Average Volume (3m)
342.35K
1-Year Change
-66.25%
Book Value / Share
0.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LGVN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.863
Upside
+1,237.72%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Longeveron LLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Longeveron LLC Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Longeveron LLC Earnings Call Summary for Q3/2025

  • Longeveron reported Q3 2025 revenue of $0.8 million, a 53% year-over-year decline, with net loss increasing 45% to $17.3 million, causing stock to fall 3.67%
  • Cash runway extended to late Q1 2026 with an at-the-market equity financing vehicle of up to $10.7 million in place to support operations
  • Company anticipates ELPASO-2 trial top-line results in Q3 2026 and plans Biologics License Application submission in 2027 for its Lomecel-B stem cell therapy
  • Despite financial challenges, Longeveron continues advancing its stem cell therapy programs, which have received five FDA designations
  • Management is actively exploring partnerships and M&A opportunities to strengthen the company's pipeline and market position in rare disease treatments
Last Updated: 2025-11-04, 05:46 p/m
Read Full Transcript

Compare LGVN to Peers and Sector

Metrics to compare
LGVN
Peers
Sector
Relationship
P/E Ratio
−0.5x−1.8x−0.5x
PEG Ratio
−0.01−0.070.00
Price/Book
1.1x2.0x2.6x
Price / LTM Sales
7.6x63.4x3.3x
Upside (Analyst Target)
-213.1%45.8%
Fair Value Upside
Unlock12.5%6.4%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.863
(+1,237.72% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 04, 2025
EPS / Forecast
-0.39 / -0.21
Revenue / Forecast
137.00K / --
EPS Revisions
Last 90 days

LGVN Income Statement

People Also Watch

0.620
IMUX
+5.26%
6.260
KPTI
+2.79%
6.0000
MNTS
+8.89%
2.8800
DFLI
+12.06%

FAQ

What Is the Longeveron LLC (LGVN) Stock Price Today?

The Longeveron LLC stock price today is 0.513

What Stock Exchange Does Longeveron LLC Trade On?

Longeveron LLC is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Longeveron LLC?

The stock symbol for Longeveron LLC is "LGVN."

What Is the Longeveron LLC Market Cap?

As of today, Longeveron LLC market cap is 10.94M.

What Is Longeveron LLC's Earnings Per Share (TTM)?

The Longeveron LLC EPS (TTM) is -1.35.

From a Technical Analysis Perspective, Is LGVN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Longeveron LLC Stock Split?

Longeveron LLC has split 1 times.

How Many Employees Does Longeveron LLC Have?

Longeveron LLC has 25 employees.

What is the current trading status of Longeveron LLC (LGVN)?

As of Feb 09, 2026, Longeveron LLC (LGVN) is trading at a price of 0.513, with a previous close of 0.511. The stock has fluctuated within a day range of 0.510 to 0.531, while its 52-week range spans from 0.492 to 1.920.

What Is Longeveron LLC (LGVN) Price Target According to Analysts?

The average 12-month price target for Longeveron LLC is USD6.863, with a high estimate of USD10.45 and a low estimate of USD3. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1,237.72% Upside potential.

What Is the LGVN After Hours Price?

LGVN's last after hours stock price is 0.511, the stock has decreased by -0.002, or -0.430%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.